Jim Cramer is doubling down on Johnson & Johnson (NYSE: JNJ), telling viewers the healthcare giant is trading at a rare discount and may not be this cheap again. The Mad Money host called J&J “one of the greatest American companies out there” and urged investors to “accumulate” while the broader market sells off. Why the optimism? J&J just secured a key FDA approval for Icotyde, an autoimmune treatment for moderate to severe psoriasis — a large, high-demand market — and Cramer says that approval has been overshadowed by recent noise in healthcare. He added that additional pipeline drugs, including Ottava and JNJ-78934804, could also win regulatory clearance, potentially unlocking more upside for the stock. Market context: JNJ has slipped more than 6% over the past month and was trading near $227, with price action largely rangebound over the past week. Cramer sees that weakness as a buying opportunity in an out-of-favor pharma sector: “You don’t get a chance to buy the best at a discount very often,” he said, advising a buy-the-dip approach — buy some now, buy more if it falls further. For crypto traders and investors watching broader markets, Cramer’s take is a reminder that traditional blue-chip healthcare plays can offer exposure to tangible drug approvals and revenue catalysts that sometimes move independently of tech and crypto cycles. As always, investors should do their own research and weigh risks before allocating capital. Read more AI-generated news on: undefined/news